Loading...
 
Back to the list
Mediterr J Rheumatol 2022;33(Suppl 1):137-41
Article Links
Treat-to-Target in Axial Spondyloarthritis: Are we there yet?
Krystel Aouad1, Bassel El-Zorkany2
Authors Information

1. Sorbonne University, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France

2. Rheumatology Department, Cairo University, Cairo, Egypt

El-Zorkany B

Keywords: Treat-to-target, management, axial spondyloarthritis
References
  1. SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015 Nov 26;373(22):2103-16.
  2. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 Jul 15;363(3):233-44.
  3. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet Lond Engl 2004 Jul 17;364(9430):263-9.
  4. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res 2020 Jun;72(6):744-60.
  5. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet Lond Engl 2015 Dec 19;386(10012):2489-98.
  6. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77(1):3-17.
  7. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014 Jan;73(1):6-16.
  8. Aouad K, Ziade N, Baraliakos X. Structural progression in axial spondyloarthritis. Joint Bone Spine 2020 Mar;87(2):131-6.
  9. Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, et al. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis 2020 Feb;79(2):193-201.
  10. Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res 2011 Nov;63 Suppl 11:S47-58.
  11. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009 Jun 1;68(Suppl 2):ii1-44.
  12. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011 Jan;70(1):47-53.
  13. Aouad K, De Craemer A-S, Carron P. Can Imaging Be a Proxy for Remission in Axial Spondyloarthritis? Rheum Dis Clin North Am 2020 May;46(2):311-25.
  14. Dougados M. Treat to target in axial spondyloarthritis: From its concept to its implementation. J Autoimmun 2020 Jun;110:102398.
  15. Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014 Aug;73(8):1455-61.
  16. Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 2016 Dec;75(12):2114-8.
  17. Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 2015 Jan;74(1):52-9.
  18. Baraliakos X, Østergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, et al. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). Clin Drug Investig 2020 Mar;40(3):269-78.
  19. Molnar C, Scherer A, Baraliakos X, Hooge M de, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2018 Jan 1;77(1):63-9.
  20. Baraliakos X, Kruse S, Auteri S, Peyrecave ND, Nurminen T, Kumke T, et al. Op0104 the Impact of Persistent Inflammatory Changes on Prevalence of Fatty Lesions in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: 4-Year Mri Results from Rapid-Axspa. Ann Rheum Dis 2020 Jun 1;79(Suppl 1):67-8.
  21. Molto A, López-Medina C, Van den Bosch FE, Boonen A, Webers C, Dernis E, et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis 2021 Nov;80(11):1436-1444.
  22. Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2015 May;74(5):830-5.
  23. Molto A, Heijde D van der, Bosch FEV den, Dougados M. Response to: ‘Correspondence on “Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial”’ by Cai and Peng. Ann Rheum Dis [Internet] 2021 Jun 29 [cited 2021 Jul 10]; Available from: https://ard.bmj.com/content/early/2021/06/28/annrheumdis-2021-220913
  24. Poddubnyy D, Hammel L, Heyne M, Veit J, Jentzsch C, Baraliakos X. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate. BMJ Open 2020 Sep 30;10(9):e039059.
  25. Danve A, Deodhar A. Treat to Target in Axial Spondyloarthritis: What Are the Issues? Curr Rheumatol Rep 2017 May;19(5):22.
  26. Aouad K, Wendling D, Baglin A, Breban M, Dadoun S, Hudry C, et al. POS0243 What does remission in axial spondyloarthritis mean for clinicians? an exploratory study of 200 french rheumatologists based on a vignette exercise including 36 cases and priority ratings. Ann Rheum Dis 2021 Jun 1;80(Suppl 1):343.
  27. Fernández-Carballido C, Collantes-Estévez E, Gratacós J, Juanola X, Zarco P. Remission in Axial Spondyloarthritis: Developing a Consensus Definition. Reumatol Clin 2020 Mar 2;S1699-258X(20)30017-6.
  28. Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, et al. Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. J Rheumatol 2018 Feb 1;45(2):153-7.
  29. Marzo-Ortega H, Gaffney KM, Gaffney K. Defining the target: clinical aims in axial spondyloarthritis. Rheumatol Oxf Engl 2018 Nov;57(Suppl 6):vi18-22.
  30. Vegas LP, Sbidian E, Wendling D, Goupille P, Ferkal S, Corvoisier PL, et al. Op0052 Factors Associated with Remission at 5 Years of Follow-up in Early Onset Axial Spondyloarthritis: Results from the Desir Cohort. Ann Rheum Dis 2021 Jun 1;80(Suppl 1):27–8.
  31. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017 Jun;76(6):978-91.
  32. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol Hoboken NJ 2019 Oct;71(10):1599-613.